WuXi Biologics (HK:2269), a China-based global Contract Research, Development and Manufacturing Organisation (CRDMO), announced on Sunday that it has achieved ISO 20400 Sustainable Procurement certification, a standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility across the supply chain.

WuXi Biologics has embedded sustainability principles across its entire system of supplier lifecycle management -- from supplier due diligence and admission, to risk management and engagement, to performance review and termination.

Dr. Chris Chen, WuXi Biologics CEO and chairman of the ESG Committee, said: "As a member and active participant of PSCI (Pharmaceutical Supply Chain Initiative), WuXi Biologics adheres to world-leading management strategies to build a robust supply chain that ultimately serves as the value chain empowering sustainable business growth. We deliver high-quality solutions to meet global client demands while making active contributions that spearhead responsible value chain advancement in the pharmaceutical industry."